Company Overview
Biodesix, Inc. operates as a specialized diagnostic solutions company focused on the healthcare sector, specifically within the diagnostics and research industry. The firm provides blood-based lung tests, including the Nodify XL2 and Nodify CDT tests, which are marketed as Nodify Lung Nodule Risk Assessment solutions designed to assess lung cancer risk and assist in identifying appropriate treatment pathways. The company's financial scale is characterized by a market capitalization of $149.35M and annual revenue of $88.50M, supported by an employee base of 334 individuals. These valuation and revenue figures indicate a mid-sized market presence within the healthcare diagnostics landscape, suggesting a firm that has established a commercial footprint while still navigating the capital-intensive phases typical of diagnostic technology development and commercialization.
Financial Health
The company reported a revenue of $88.50M over the trailing twelve months, yet it posted a net income of -$35,265,000 and an EBITDA of -$22,096,000. The substantial gap between the positive revenue of $88.50M and the negative net income reveals a cost structure where operating expenses and other deductions significantly outweigh gross profits, resulting in a profit margin of -39.8%. While the gross margin stands at a robust 81.1%, indicating high efficiency in production or service delivery relative to direct costs, the operating margin of -6.8% and the overall profit margin of -39.8% highlight significant overhead pressures or R&D expenditures that are currently eroding profitability. The free cash flow stands at -$11,825,250, which implies that the company is burning cash from its operations and investing heavily in growth initiatives, limiting immediate financial flexibility but potentially building long-term value. On the liability side, the company holds $18.99M in cash against $75.03M in debt, and the debt-to-equity ratio is listed as N/A due to the negative equity position derived from the loss-making status. Despite the high debt load, the current ratio of 1.86 suggests that the company maintains adequate short-term liquidity to cover its current liabilities with its current assets. Return on Equity is -383.1% and Return on Assets is -18.8%, metrics that reveal management has not yet generated positive returns on the capital invested, reflecting the early-stage or high-investment nature of the business model before reaching a break-even threshold.
Valuation Assessment
The trailing P/E ratio is N/A because the company has not generated positive net income, while the forward P/E is -68.86, a metric that is not meaningful for valuing a loss-making firm but indicates the market is pricing in future earnings expectations. The price-to-book ratio is -50.67, which indicates a negative valuation relative to book value, often seen in biotech or diagnostic firms where intangible assets and future potential outweigh current asset valuations. Alternative valuation metrics such as the price-to-sales ratio of 1.69 and an EV/EBITDA of -9.30 suggest the market is valuing the company primarily on its revenue generation capabilities rather than current profitability. The stock's 52-week trading range spans from a low of $3.44 to a high of $20.21, providing a clear view of the price volatility experienced over the last year. The current price sits at a level that reflects a significant premium above the 52-week low of $3.44, indicating strong recent performance relative to the yearly floor, though the specific percentage distance from the high depends on the current market price which fluctuates. The beta value is 0.57, which implies that the stock's price volatility is lower than the broader market, suggesting it may be less sensitive to general market swings than large-cap technology or financial stocks.
Growth & Income
The company demonstrated a revenue growth rate of 40.8% year-over-year, whereas earnings growth is N/A due to the absence of positive earnings. Since earnings are not growing faster than revenue because the company is currently unprofitable, the 40.8% revenue expansion indicates strong top-line demand for the blood-based lung tests, while the lack of earnings growth highlights the heavy cost structure consuming those revenues. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the firm reinvests all available cash flow back into research, development, and operational scaling rather than distributing income to shareholders. This non-dividend profile is typical for growth-stage diagnostic companies that prioritize expanding their market share and refining their test technologies over providing immediate income returns. Overall, the growth and income profile for Biodesix, Inc. is defined by aggressive top-line expansion coupled with a complete absence of current profitability or dividend distributions, positioning the asset as a high-risk, high-potential growth play in the healthcare diagnostics sector.